$PFE News U.S. stocks fall; Nasdaq 3-day loss
Post# of 102254
Posted On: 04/09/2014 7:33:57 PM
$PFE News
U.S. stocks fall; Nasdaq 3-day loss worst since 2011 4:48 p.m. April 7, 2014 - Victor Reklaitis
Newscast: Wall Street extends recent selloff 4:28 p.m. April 7, 2014 - MarketWatch
Tesla, Facebook seesaw; Questcor surges on deal 3:54 p.m. April 7, 2014 - Ben Eisen
Pfizer shares drop despite positive test for breast-cancer drug 1:03 p.m. April 7, 2014 - blogs.marketwatch.com
Pfizer drops 2.5% to lead Dow decliners 9:35 a.m. April 7, 2014 - William L. Watts
How sector stock funds can make your portfolio whole 7:01 a.m. April 7, 2014 - Jonathan Burton
Best, worst stocks of the $100 billion club: Morgan Stanley 2:03 p.m. March 31, 2014 - blogs.marketwatch.com
Pfizer anti-cholesterol drug meets main study goal 9:28 a.m. March 27, 2014 - MarketWatch.com
Apple looks ready to head higher 3:48 p.m. March 17, 2014 - blogs.marketwatch.com
Apple as the Comeback Kid 1:13 p.m. March 13, 2014 - Mark Hulbert
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Pfizer loses ruling on Celebrex patent dispute 2:46 p.m. March 12, 2014 - Russ Britt
Trading resumes on Pfizer shares 2:37 p.m. March 12, 2014 - Russ Britt
Ruling invalidates Pfizer's Celebrex patent 2:36 p.m. March 12, 2014 - Russ Britt
Pfizer obtained reissue patent on Celebrex in 2013 2:35 p.m. March 12, 2014 - Russ Britt
Pfizer plans to appeal ruling on Celebrex judgment 2:31 p.m. March 12, 2014 - Russ Britt
Pfizer loses ruling on Celebrex patent dispute 2:30 p.m. March 12, 2014 - Russ Britt
Pfizer halted 2:15 p.m. March 12, 2014 - Steve Goldstein
S&P 500 extends the break to 'clear skies' territory 10:46 a.m. March 6, 2014 - Michael Ashbaugh
A Favorable Look at Pfizer and Signet 52 min ago - Barrons.com
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. Today - TheStreet.com
Teva to Launch Generic Lovaza - Analyst Blog 4:45 p.m. Today - Zacks.com
3 Stocks Reiterated As A Buy: PFE, GE, MCD 2:44 p.m. Today - TheStreet.com
Dow Today: Pfizer (PFE) Lower 1:00 p.m. Today - TheStreet.com
Top 10 Net Payout Yield Stocks For April 2014 11:19 a.m. Today - Seeking Alpha
Pfizer: It Never Rains, It Pours 7:24 a.m. Today - Seeking Alpha
Wall Street Breakfast: Must-Know News 6:31 a.m. Today - Seeking Alpha
Update on Merck's MK-3475 - Analyst Blog 6:35 p.m. April 8, 2014 - Zacks.com
A Sharp Pullback In Celldex Could Be A Window Of Opportunity 3:41 p.m. April 8, 2014 - Seeking Alpha
Is Buy and Hold Dead? 2:45 p.m. April 8, 2014 - RealMoney.com
The Bottom Is Nowhere in Sight 11:00 a.m. April 8, 2014 - RealMoney.com
Pfizer: Buy the Dip 10:51 a.m. April 8, 2014 - Barrons.com
Use Norway Sovereign Fund's Top Holdings To Your Own Advantage 10:47 a.m. April 8, 2014 - Seeking Alpha
Encouraging Results from Pfizer's Palbociclib - Analyst Blog 10:40 a.m. April 8, 2014 - Zacks.com
Can GlaxoSmithKline Recover? 10:13 a.m. April 8, 2014 - Wall St. Cheat Sheet
Stock Market News for April 08, 2014 - Market News 10:06 a.m. April 8, 2014 - Zacks.com
The 4 Stocks That Slammed the Market 3:44 p.m. April 7, 2014 - 247WallSt.com
Why Pfizer (PFE) Stock Is Down On Monday 2:45 p.m. April 7, 2014 - TheStreet.com
Pfizer Breast-Cancer Drug Scores, But Street Cautious 10:23 a.m. April 7, 2014 - Investors Business Daily
Thyroid Cancer Global Clinical Trials Review, H2, 2013 1:29 p.m. Today - PR Newswire - PRF
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma 8:00 a.m. Today - PR Newswire - PRF
Diabetic Macular Edema Global Clinical Trials Review, H2, 2013 10:32 a.m. April 8, 2014 - PR Newswire - PRF
NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept 8:00 a.m. April 7, 2014 - PR Newswire - PRF
Pfizer's Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer 10:30 a.m. April 6, 2014 - BusinessWire - BZX
AMCP Foundation Launches Initiative to Identify Emerging Medication Management Practices that Can Advance Patient Care and Outcomes; Project Supported by Pfizer 12:38 p.m. April 3, 2014 - PR Newswire - PRF
Exosomes Shine a Light on Alzheimer's Disease and CTE 10:16 a.m. April 3, 2014 - ACCESSWIRE
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool 2:30 p.m. April 1, 2014 - PR Newswire - PRF
LabCentral Announces Sponsorship by Pfizer to Support Life-Science Startup Companies in Cambridge, Massachusetts 8:30 a.m. April 1, 2014 - PR Newswire - PRF
Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR 6:26 p.m. March 28, 2014 - BusinessWire - BZX
Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices 11:31 a.m. March 28, 2014 - PR Newswire - PRF
Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan 8:00 a.m. March 28, 2014 - PR Newswire - PRF
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. March 27, 2014 - BusinessWire - BZX
Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1 8:02 a.m. March 27, 2014 - BusinessWire - BZX
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age 8:01 a.m. March 26, 2014 - BusinessWire - BZX
Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts 5:10 p.m. March 25, 2014 - BusinessWire - BZX
Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) 8:30 a.m. March 25, 2014 - BusinessWire - BZX
Renaissance Technologies Buys Stake in Pfizer; Yahoo Looks to Profit from Alibaba IPO 12:21 a.m. March 25, 2014 - ACCESSWIRE
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 11:45 a.m. March 22, 2014 - BusinessWire - BZX
U.S. stocks fall; Nasdaq 3-day loss worst since 2011 4:48 p.m. April 7, 2014 - Victor Reklaitis
Newscast: Wall Street extends recent selloff 4:28 p.m. April 7, 2014 - MarketWatch
Tesla, Facebook seesaw; Questcor surges on deal 3:54 p.m. April 7, 2014 - Ben Eisen
Pfizer shares drop despite positive test for breast-cancer drug 1:03 p.m. April 7, 2014 - blogs.marketwatch.com
Pfizer drops 2.5% to lead Dow decliners 9:35 a.m. April 7, 2014 - William L. Watts
How sector stock funds can make your portfolio whole 7:01 a.m. April 7, 2014 - Jonathan Burton
Best, worst stocks of the $100 billion club: Morgan Stanley 2:03 p.m. March 31, 2014 - blogs.marketwatch.com
Pfizer anti-cholesterol drug meets main study goal 9:28 a.m. March 27, 2014 - MarketWatch.com
Apple looks ready to head higher 3:48 p.m. March 17, 2014 - blogs.marketwatch.com
Apple as the Comeback Kid 1:13 p.m. March 13, 2014 - Mark Hulbert
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Pfizer loses ruling on Celebrex patent dispute 2:46 p.m. March 12, 2014 - Russ Britt
Trading resumes on Pfizer shares 2:37 p.m. March 12, 2014 - Russ Britt
Ruling invalidates Pfizer's Celebrex patent 2:36 p.m. March 12, 2014 - Russ Britt
Pfizer obtained reissue patent on Celebrex in 2013 2:35 p.m. March 12, 2014 - Russ Britt
Pfizer plans to appeal ruling on Celebrex judgment 2:31 p.m. March 12, 2014 - Russ Britt
Pfizer loses ruling on Celebrex patent dispute 2:30 p.m. March 12, 2014 - Russ Britt
Pfizer halted 2:15 p.m. March 12, 2014 - Steve Goldstein
S&P 500 extends the break to 'clear skies' territory 10:46 a.m. March 6, 2014 - Michael Ashbaugh
A Favorable Look at Pfizer and Signet 52 min ago - Barrons.com
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. Today - TheStreet.com
Teva to Launch Generic Lovaza - Analyst Blog 4:45 p.m. Today - Zacks.com
3 Stocks Reiterated As A Buy: PFE, GE, MCD 2:44 p.m. Today - TheStreet.com
Dow Today: Pfizer (PFE) Lower 1:00 p.m. Today - TheStreet.com
Top 10 Net Payout Yield Stocks For April 2014 11:19 a.m. Today - Seeking Alpha
Pfizer: It Never Rains, It Pours 7:24 a.m. Today - Seeking Alpha
Wall Street Breakfast: Must-Know News 6:31 a.m. Today - Seeking Alpha
Update on Merck's MK-3475 - Analyst Blog 6:35 p.m. April 8, 2014 - Zacks.com
A Sharp Pullback In Celldex Could Be A Window Of Opportunity 3:41 p.m. April 8, 2014 - Seeking Alpha
Is Buy and Hold Dead? 2:45 p.m. April 8, 2014 - RealMoney.com
The Bottom Is Nowhere in Sight 11:00 a.m. April 8, 2014 - RealMoney.com
Pfizer: Buy the Dip 10:51 a.m. April 8, 2014 - Barrons.com
Use Norway Sovereign Fund's Top Holdings To Your Own Advantage 10:47 a.m. April 8, 2014 - Seeking Alpha
Encouraging Results from Pfizer's Palbociclib - Analyst Blog 10:40 a.m. April 8, 2014 - Zacks.com
Can GlaxoSmithKline Recover? 10:13 a.m. April 8, 2014 - Wall St. Cheat Sheet
Stock Market News for April 08, 2014 - Market News 10:06 a.m. April 8, 2014 - Zacks.com
The 4 Stocks That Slammed the Market 3:44 p.m. April 7, 2014 - 247WallSt.com
Why Pfizer (PFE) Stock Is Down On Monday 2:45 p.m. April 7, 2014 - TheStreet.com
Pfizer Breast-Cancer Drug Scores, But Street Cautious 10:23 a.m. April 7, 2014 - Investors Business Daily
Thyroid Cancer Global Clinical Trials Review, H2, 2013 1:29 p.m. Today - PR Newswire - PRF
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma 8:00 a.m. Today - PR Newswire - PRF
Diabetic Macular Edema Global Clinical Trials Review, H2, 2013 10:32 a.m. April 8, 2014 - PR Newswire - PRF
NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept 8:00 a.m. April 7, 2014 - PR Newswire - PRF
Pfizer's Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer 10:30 a.m. April 6, 2014 - BusinessWire - BZX
AMCP Foundation Launches Initiative to Identify Emerging Medication Management Practices that Can Advance Patient Care and Outcomes; Project Supported by Pfizer 12:38 p.m. April 3, 2014 - PR Newswire - PRF
Exosomes Shine a Light on Alzheimer's Disease and CTE 10:16 a.m. April 3, 2014 - ACCESSWIRE
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool 2:30 p.m. April 1, 2014 - PR Newswire - PRF
LabCentral Announces Sponsorship by Pfizer to Support Life-Science Startup Companies in Cambridge, Massachusetts 8:30 a.m. April 1, 2014 - PR Newswire - PRF
Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR 6:26 p.m. March 28, 2014 - BusinessWire - BZX
Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices 11:31 a.m. March 28, 2014 - PR Newswire - PRF
Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan 8:00 a.m. March 28, 2014 - PR Newswire - PRF
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. March 27, 2014 - BusinessWire - BZX
Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1 8:02 a.m. March 27, 2014 - BusinessWire - BZX
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age 8:01 a.m. March 26, 2014 - BusinessWire - BZX
Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts 5:10 p.m. March 25, 2014 - BusinessWire - BZX
Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) 8:30 a.m. March 25, 2014 - BusinessWire - BZX
Renaissance Technologies Buys Stake in Pfizer; Yahoo Looks to Profit from Alibaba IPO 12:21 a.m. March 25, 2014 - ACCESSWIRE
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 11:45 a.m. March 22, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼